Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Oklahoma Medical Research Foundation
848
mi
from 43215
Oklahoma City, OK
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Oklahoma Medical Research Foundation
848
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
910
mi
from 43215
Dallas, TX
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Emory University
435
mi
from 43215
Atlanta, GA
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Emory University
435
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Hospital of St. Raphael
538
mi
from 43215
New Haven, CT
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Hospital of St. Raphael
538
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Tulane University Health Sciences Center
797
mi
from 43215
New Orleans, LA
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Tulane University Health Sciences Center
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Creighton University
683
mi
from 43215
Omaha, NE
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Creighton University
683
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Regional Surgical Associates
354
mi
from 43215
Durham, NC
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Regional Surgical Associates
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Oregon Health and Sciences University
2026
mi
from 43215
Portland, OR
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Oregon Health and Sciences University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated:  2/22/2016
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
Strattice in Repair of Inguinal Hernias
Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias
Status: Enrolling
Updated: 2/22/2016
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated:  2/24/2016
Clinical Research Facility
621
mi
from 43215
Fairway, KA
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated: 2/24/2016
Clinical Research Facility
621
mi
from 43215
Fairway, KA
Click here to add this to my saved trials
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated:  2/24/2016
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated: 2/24/2016
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated:  2/24/2016
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated: 2/24/2016
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated:  2/24/2016
Clinical Research Facility
991
mi
from 43215
Houston, TX
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Status: Enrolling
Updated: 2/24/2016
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Central Hematology/Oncology Medical Group, Inc.
1965
mi
from 43215
Alhambra, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Central Hematology/Oncology Medical Group, Inc.
1965
mi
from 43215
Alhambra, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Comprehensive Blood and Cancer Center
1983
mi
from 43215
Bakersfield, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Comprehensive Blood and Cancer Center
1983
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center
1958
mi
from 43215
Fullerton, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center
1958
mi
from 43215
Fullerton, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Antelope Valley Cancer Center
1950
mi
from 43215
Lancaster, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Antelope Valley Cancer Center
1950
mi
from 43215
Lancaster, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Pacific Shores Medical Group
1976
mi
from 43215
Long Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Pacific Shores Medical Group
1976
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Jonsson Comprehensive Cancer Center at UCLA
1982
mi
from 43215
Los Angeles, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Jonsson Comprehensive Cancer Center at UCLA
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Translational Oncology Research International (TORI) Network
1982
mi
from 43215
Los Angeles, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Translational Oncology Research International (TORI) Network
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Wilshire Oncology Medical Group, Inc.
1944
mi
from 43215
Pomona, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Wilshire Oncology Medical Group, Inc.
1944
mi
from 43215
Pomona, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Cancer Care Associates Medical Group, Inc.
1985
mi
from 43215
Redondo Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Cancer Care Associates Medical Group, Inc.
1985
mi
from 43215
Redondo Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.)
1985
mi
from 43215
Redondo Beach, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.)
1985
mi
from 43215
Redondo Beach, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
2042
mi
from 43215
Santa Barbara, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Santa Barbara Hematology Oncology Medical Group, Inc.
2042
mi
from 43215
Santa Barbara, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Sansum Medical Clinic
2042
mi
from 43215
Santa Barbara, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Sansum Medical Clinic
2042
mi
from 43215
Santa Barbara, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Central Coast Medical Oncology Corporation
2064
mi
from 43215
Santa Maria, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Central Coast Medical Oncology Corporation
2064
mi
from 43215
Santa Maria, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Trivalley Oncology Hematology
2002
mi
from 43215
Westlake Village, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Trivalley Oncology Hematology
2002
mi
from 43215
Westlake Village, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
North Valley Hematology-Oncology Medical Group
1982
mi
from 43215
Northridge, CA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
North Valley Hematology-Oncology Medical Group
1982
mi
from 43215
Northridge, CA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Suburban Hematology/Oncology Associates, Pc
418
mi
from 43215
Lawrenceville, GA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Suburban Hematology/Oncology Associates, Pc
418
mi
from 43215
Lawrenceville, GA
Click here to add this to my saved trials
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated:  2/26/2016
Northwest Georgia Oncology Centers, PC
425
mi
from 43215
Marietta, GA
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Status: Enrolling
Updated: 2/26/2016
Northwest Georgia Oncology Centers, PC
425
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation
Status: Enrolling
Updated:  2/29/2016
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation
Status: Enrolling
Updated: 2/29/2016
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis: A Prospective Correlation With Intraoperative Findings and Surgical Pathology
Status: Enrolling
Updated:  2/29/2016
Indiana University Hospital
167
mi
from 43215
Indianapolis, IN
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis: A Prospective Correlation With Intraoperative Findings and Surgical Pathology
Status: Enrolling
Updated: 2/29/2016
Indiana University Hospital
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
Status: Enrolling
Updated:  3/1/2016
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
Status: Enrolling
Updated: 3/1/2016
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Factors Associated With End Stage Liver Disease
Factors Associated With End Stage Liver Disease
Status: Enrolling
Updated:  3/1/2016
NYU School of Medicine, Schwartz Health Care Center Suite 4C
478
mi
from 43215
New York, NY
Factors Associated With End Stage Liver Disease
Factors Associated With End Stage Liver Disease
Status: Enrolling
Updated: 3/1/2016
NYU School of Medicine, Schwartz Health Care Center Suite 4C
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
Status: Enrolling
Updated:  3/1/2016
New York University Langone Medical Center
479
mi
from 43215
New York, NY
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
Status: Enrolling
Updated: 3/1/2016
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
Status: Enrolling
Updated:  3/1/2016
Duke University
352
mi
from 43215
Durham, NC
A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
Status: Enrolling
Updated: 3/1/2016
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
Status: Enrolling
Updated:  3/1/2016
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
Status: Enrolling
Updated: 3/1/2016
Cedars-Sinai Medical Center
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated:  3/1/2016
UCSF-Fresno University
1990
mi
from 43215
Fresno, CA
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated: 3/1/2016
UCSF-Fresno University
1990
mi
from 43215
Fresno, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated:  3/1/2016
Loma Linda University Medical Center
1919
mi
from 43215
Loma Linda, CA
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated: 3/1/2016
Loma Linda University Medical Center
1919
mi
from 43215
Loma Linda, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated:  3/1/2016
Permian Research Foundation
1215
mi
from 43215
Odessa, TX
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy
Status: Enrolling
Updated: 3/1/2016
Permian Research Foundation
1215
mi
from 43215
Odessa, TX
Click here to add this to my saved trials
Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island
Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island: Active Hospital-Based Surveillance, Serotype Surveillance and a Case-Control Study
Status: Enrolling
Updated:  3/1/2016
Hasbro Children's Hospital
619
mi
from 43215
Providence, RI
Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island
Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island: Active Hospital-Based Surveillance, Serotype Surveillance and a Case-Control Study
Status: Enrolling
Updated: 3/1/2016
Hasbro Children's Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Status: Enrolling
Updated:  3/2/2016
Helen L. & Martin S. Kimmel Wound Healing Center at the NYU Hospital for Joint Diseases
477
mi
from 43215
New York, NY
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Status: Enrolling
Updated: 3/2/2016
Helen L. & Martin S. Kimmel Wound Healing Center at the NYU Hospital for Joint Diseases
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.
Status: Enrolling
Updated:  3/2/2016
North Carolina Clinical and Translational Research Center
328
mi
from 43215
Chapel Hill, NC
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.
Status: Enrolling
Updated: 3/2/2016
North Carolina Clinical and Translational Research Center
328
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Transforming Opioid Prescribing in Primary Care
Implementing Opioid Risk Reduction Strategies Into Primary Care Practice
Status: Enrolling
Updated:  3/2/2016
Boston Med Ctr
642
mi
from 43215
Boston, MA
Transforming Opioid Prescribing in Primary Care
Implementing Opioid Risk Reduction Strategies Into Primary Care Practice
Status: Enrolling
Updated: 3/2/2016
Boston Med Ctr
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Nerve Growth Factor in Chronic Pancreatitis
Nerve Growth Factor in Chronic Pancreatitis
Status: Enrolling
Updated:  3/3/2016
VCU Medical Center
344
mi
from 43215
Richmond, VA
Nerve Growth Factor in Chronic Pancreatitis
Nerve Growth Factor in Chronic Pancreatitis
Status: Enrolling
Updated: 3/3/2016
VCU Medical Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Eosinophilic Esophagitis Databank
Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)
Status: Enrolling
Updated:  3/3/2016
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Eosinophilic Esophagitis Databank
Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)
Status: Enrolling
Updated: 3/3/2016
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Eosinophilic Esophagitis Databank
Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)
Status: Enrolling
Updated:  3/3/2016
National Jewish Health
1160
mi
from 43215
Denver, CO
Eosinophilic Esophagitis Databank
Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)
Status: Enrolling
Updated: 3/3/2016
National Jewish Health
1160
mi
from 43215
Denver, CO
Click here to add this to my saved trials